内分泌治疗在乳腺癌中的免疫调节作用。
The immunomodulatory effects of endocrine therapy in breast cancer.
机构信息
Department of Breast Surgery, Second Affiliated Hospital Zhejiang University, Zhejiang, 310009, Hangzhou, China.
Key Laboratory of Tumour Microenvironment and Immune Therapy of Zhejiang Province, Second Affiliated Hospital Zhejiang University, Zhejiang, 310009, Hangzhou, China.
出版信息
J Exp Clin Cancer Res. 2021 Jan 7;40(1):19. doi: 10.1186/s13046-020-01788-4.
Endocrine therapies with SERMs (selective estrogen receptor modulators) or SERDs (selective estrogen receptor downregulators) are standard therapies for patients with estrogen receptor (ER)-positive breast cancer. Multiple small molecule inhibitors targeting the PI3K-AKT-mTOR pathway or CDK4/6 have been developed to be used in combination with anti-estrogen drugs to overcome endocrine resistance. In addition to their direct antitumor effects, accumulating evidence has revealed the tumor immune microenvironment (TIM)-modulating effects of these therapeutic strategies, which have not been properly acknowledged previously. The immune microenvironment of breast tumors plays a crucial role in tumor development, metastasis and treatment response to endocrine therapy and immunotherapy. Therefore, in our current work, we comprehensively review the immunomodulatory effect of endocrine therapy and discuss its potential applications in combination with immune checkpoint inhibitors in breast cancer treatment.
内分泌治疗联合 SERMs（选择性雌激素受体调节剂）或 SERDs（选择性雌激素受体降解剂）是雌激素受体阳性乳腺癌患者的标准治疗方法。为了克服内分泌耐药性，已经开发出多种针对 PI3K-AKT-mTOR 通路或 CDK4/6 的小分子抑制剂，与抗雌激素药物联合使用。除了直接的抗肿瘤作用外，越来越多的证据揭示了这些治疗策略的肿瘤免疫微环境（TIM）调节作用，而这些作用以前并未得到适当的认可。乳腺肿瘤的免疫微环境在肿瘤的发展、转移以及对内分泌治疗和免疫治疗的反应中起着至关重要的作用。因此，在我们目前的工作中，我们全面综述了内分泌治疗的免疫调节作用，并讨论了其与免疫检查点抑制剂联合应用于乳腺癌治疗的潜在应用。
Zotero 插件